James J. Dignam to Risk
This is a "connection" page, showing publications James J. Dignam has written about Risk.
Connection Strength
0.169
-
The use and interpretation of competing risks regression models. Clin Cancer Res. 2012 Apr 15; 18(8):2301-8.
Score: 0.092
-
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 May 01; 5(5):664-670.
Score: 0.038
-
Multiple imputation methods for inference on cumulative incidence with missing cause of failure. Biom J. 2011 Nov; 53(6):974-93.
Score: 0.023
-
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19; 89(22):1673-82.
Score: 0.009
-
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996 Nov 06; 88(21):1529-42.
Score: 0.008